REal World Data in LYmphoma and Survival in Adults

  • End date
    Nov 14, 2027
  • participants needed
  • sponsor
    Hospices Civils de Lyon
Updated on 4 July 2021
follicular lymphoma
diffuse large b-cell lymphoma
b-cell lymphoma
mantle cell lymphoma
t-cell lymphoma
marginal zone lymphoma
large b-cell lymphoma


REALYSA cohort is a population-based epidemiological platform in real-life for lymphomas designed to enrich prognostic data, by integrating together epidemiological, clinical and biological data.

REALYSA is a platform perfectly set up to

  • Study prognostic factors using integrated epidemiological and biological data (genetics), to better characterize the determinants of refractoriness and relapse in patients with lymphoma, to follow the growing number of survivors and describe median to long-term sequela, second cancer, quality of life (QoL)
  • Document treatment effectiveness in real life and observance
  • Address socio-economical questions

Condition Mantle cell lymphoma, hodgkin's lymphoma, Burkitt Lymphoma (BL)), Hodgkin's Disease, T-Cell Lymphoma, Mantle Cell Lymphoma, Lymphoma, Diffuse Large B Lymphoma (DLBCL), t cell lymphoma, Follicular Lymphoma, hodgkins lymphoma, hodgkin's lymphomas, Marginal Zone Lymphoma, Non-Hodgkin's Lymphoma, hodgkin, hodgkin lymphomas, MALT Lymphoma
Treatment Real-life epidemiological platform of lymphoma in France
Clinical Study IdentifierNCT03869619
SponsorHospices Civils de Lyon
Last Modified on4 July 2021


Yes No Not Sure

Inclusion Criteria

Signature of the consent form for participation in the REALYSA cohort
Aged over 18 at the time of inclusion
Diagnosed with lymphoma in the last 6 months (180 days)
Lymphoma subtype belonging to at least one of the 7 histological subtypes: diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, T-cell lymphoma, Hodgkin's lymphoma, Burkitt lymphoma

Exclusion Criteria

Anti-lymphoma treatment already received (except pre-phase: typically corticosteroids, vincristine, cyclophosphamide, etoposide, alone or in combination)
Documented HIV infection
Any other lymphoma subtype not included in the list in Appendix 1. Of note, are
Chronic lymphocytic leukemia/small lymphocytic lymphoma
Hairy cell leukemia and variant
Lymphoplasmacytic lymphoma
Waldenstrm macroglobulinemia
Primary DLBCL of the central nervous system (CNS)
T-cell large granular lymphocytic leukemia
Chronic lymphoproliferative disorder of NK cells
Mycosis fungoides
Szary syndrome
Primary cutaneous T cell lymphomas (mainly diagnosed and treated by dermatologists)
Post-transplant lymphoproliferative disorders (PTLD)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note